"Citalopram" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition.
| Descriptor ID |
D015283
|
| MeSH Number(s) |
D02.092.831.170 D02.626.320 D03.633.100.127.187
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Citalopram".
Below are MeSH descriptors whose meaning is more specific than "Citalopram".
This graph shows the total number of publications written about "Citalopram" by people in this website by year, and whether "Citalopram" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 6 | 0 | 6 |
| 2016 | 4 | 1 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Citalopram" by people in Profiles.
-
Inflammation-Induced Histamine Impairs the Capacity of Escitalopram to Increase Hippocampal Extracellular Serotonin. J Neurosci. 2021 07 28; 41(30):6564-6577.
-
Prescribing Trend of Inappropriate Medications in Outpatient Clinics for Older Adults With Heart Failure in the United States: NAMCS 2012 to 2016. Am J Cardiol. 2021 Aug 01; 152:168.
-
High-fat diet induces neuroinflammation and reduces the serotonergic response to escitalopram in the hippocampus of obese rats. Brain Behav Immun. 2021 08; 96:63-72.
-
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436.
-
Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease. Am J Alzheimers Dis Other Demen. 2018 11; 33(7):450-457.
-
Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Affect Disord. 2016 Dec; 206:151-160.
-
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. Br J Clin Pharmacol. 2016 09; 82(3):784-92.
-
Principal components analysis of agitation outcomes in Alzheimer's disease. J Psychiatr Res. 2016 08; 79:4-7.
-
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. Am J Psychiatry. 2016 May 01; 173(5):473-80.
-
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.